| Literature DB >> 30210529 |
Eleonora Napoli1, Andrea Schneider2,3, Randi Hagerman2,3, Gyu Song1, Sarah Wong1, Flora Tassone2,4, Cecilia Giulivi1,2.
Abstract
Mitochondrial dysfunction (MD) has been identified in lymphocytes, fibroblasts and brain samples from adults carrying a 55-200 CGG expansion in the fragile X mental retardation 1 (FMR1) gene (premutation; PM); however, limited data are available on the bioenergetics of pediatric carriers. Here we discuss a case report of three PM carriers: two monozygotic twins (aged 8 years) harboring an FMR1 allele with 150-180 CGG repeats, with no cognitive or intellectual issues but diagnosed with depression, mood instability and ADHD, and their mother (asymptomatic carrier with 78 CGG repeats). Fibroblasts and lymphocytes from the twins presented a generalized OXPHOS deficit, altered mitochondrial network, accumulation of depolarized mitochondria, and increased mitochondrial ROS production, outcomes distinct and more severe than the mother's ones, suggesting the involvement of modulatory effects mediated by CGG expansion, X-activation ratio, sex hormones and epigenetic factors (chronic inflammation, consequence of Lyme disease). The degree of the severity of MD appeared to segregate with the morbidity of the phenotype. The mitochondrial ROS-mediated HIF-1α stabilization was identified as a key player at contributing to the MD, pointing it as a novel target for future therapeutical intervention.Entities:
Keywords: FXTAS; bioenergetics; mitochondrial dysfunction; oxidative stress; premutation
Year: 2018 PMID: 30210529 PMCID: PMC6119880 DOI: 10.3389/fgene.2018.00338
Source DB: PubMed Journal: Front Genet ISSN: 1664-8021 Impact factor: 4.599
Clinical and medication history of Pre twins analyzed in this study.
| Twin 1 | Twin 2 | |
|---|---|---|
| Sitting independently (ref. 3–8 m) | 6 | 6 |
| Crawling (ref. 5–13 m) | 10 | 9 |
| Walking (ref. 8–18 m) | 15 | 14 |
| First words (ref. 12–18 m) | 24 | 24 |
| First sentences (ref. 24 m) | 42 | 42 |
| Blood pressure [mmHg [percentile] ( | 88/56 [<50th] | 93/50 [50th] |
| Head circumference [cm [percentile] ( | 52.5 [50th] | 52.5 [50th] |
| Height [cm [percentile] ( | 118.1 [15th ] | 119.9 [19.6th] |
| Weight [kg [percentile] ( | 18.96 [3.8th] | 22.5 [34th] |
| Body Mass Index [percentile] ( | 13.6 [3rd] | 15.6 [47th] |
| Full scale IQ ( | 123 [94th] | 99 [47th] |
| Lisdexamfetamine (VyvanseTM) (past) | Yes | No |
| Risperidone (RisperdalTM) (past) | No | Yes (0.5 mg) |
| Methylphenidate (ConcertaTM) (current) | Yes | Yes (18 mg) |
| Guanfacine (TenexTM) (current) | Yes | Yes |
| Sertraline (ZoloftTM) (current) | Yes (50 mg) | Yes (25 mg) |
| Melatonin (current) | Yes | No |
| Yes (250 mg) | Yes (300 mg) | |
| Vitamin B complex (current) | Yes | Yes |
| Omega 3s (current) | Yes | Yes |
| Aripiprazole (AbilifyTM) (current) | Yes | Yes |
Major depressive episode (age 5) in partial remission Agoraphobia without history of panic disorder (age 5–7) in partial remission, specific phobia (animal type). ADHD combined type Eating disorder NOS in full remission. Sub-threshold evidence of enuresis (not full clinical criteria) | Depressive disorder NOS (age 7) in partial remission Bipolar disorder NOS ADHD combined type Evidence of mania current and past Motor coordination problems Poor stamina after Lyme disease | |
Recurrent ear infections Inguinal hernia repair (age 3.5) Reactive airway disease intermittently treated with a bronchodilator inhaler and occasional use of oral steroids and more frequent use of nasal steroids | Recurrent ear infections Umbilical hernia resolved in the first few years of life and recent repair of a right inguinal hernia Reactive airway disease and seasonal allergies Lyme disease (age 6) with erythema under his arms | |
NOS, Not Otherwise Specified; ADHD, Attention Deficit Hyperactivity Disorder; ∗diagnosis criteria for behavioral traits = KSADS or the Kiddie-schedule for affective disorders and schizophrenia. Developmental milestones normative values as well as other normative values were obtained from (National Research Council and Institute of Medicine, 2000; Wechsler, 2003; WHO Multicentre Growth Reference Study Group, 2006).
Triplet expansion, gene expression and methylation in FMR1 gene in samples from premutation carriers∗.
| Outcome | Tissue | Controls | Twin 1 | Twin 2 | Mother |
|---|---|---|---|---|---|
| CGG repeats in each allele | Lymphocytes∗ | 28 ± 2 | Premutation smear∗∗ | Premutation smear∗∗∗ | 43, 78 |
| Fibroblasts | 30 ± 1 | Premutation smear∗∗ | Premutation smear∗∗∗ | 43, 78 | |
| Lymphocytes∗ | 1 | 5.3 | 4.2 | 2.3 | |
| Fibroblasts | 1 | 1.3 | −1.3 | 1.1 | |
| Methylation on | Lymphocytes∗ | <1% | 3% | <2% | XAR = 0.15 |
| Q. 0. | Fibroblasts | NA | 8% | 3% | XAR = 0.17 |
(a) Control values (n = 12) have been published in Napoli et al. (2016b). (b)Control values (n = 12) have been published in Napoli et al. (2016a). (c) Control values were obtained from either male children (n = 5) with an average age of 8.8 ± 0.8 year (mean ± SEM) or adult females (n = 5) with an average age of 39.8 ± 2.5 year (mean ± SEM). (d) Taken from Tassone et al. (2000). ¶ Fold change referred to age- and sex-matched controls. ∗Analyses were performed in August 2013. ∗∗CGG = series of alleles throughout the premutation range with main alleles at 157 and 180 (see Figure ). ∗∗∗CGG = series of alleles throughout the premutation range with main alleles at 138 and 162 CGG (see Figure ). NA, not available. XAR, X-activation ratio.
Mitochondrial outcomes in lymphocytes from premutation twins and their parents.
| Outcome | Children controls¶ ( | Twin 1 | Twin 2 | Adult controls ( | Mother | Father |
|---|---|---|---|---|---|---|
| Malate-glutamate∗ | 1.6 ± 0.1 [1.4–1.8] | 1.2 ± 0.2 [0.7–1.7] | ||||
| Succinate∗ | 1.6 ± 0.2 [1.1–2.1] | 1.4 ± 0.2 [0.9–1.9] | ||||
| Complex IV activity ∗ | 2.1 ± 0.4 [1.2–3.0] | 2.2 ± 0.4 [1.2–3.2] | 1.4 ± 0.6 | |||
| Citrate synthase activity∗ | 15 ± 2 [10–20] | 7.6 ± 0.4 [6.6–8.6] | ||||
| CCO/CS | 0.14 ± 0.02 [0.09-0.19] | 0.10 ± 0.05 | 0.17 ± 0.06 | 0.29 ± 0.06 [0.14–0.44] | 0.6 ± 0.3 | 0.9 ± 0.4 |
| RCRu | 3.2 ± 0.3 [2.5–3.9] | 3.0 ± 2.0 | 4.8 ± 3.0 | 8 ± 2 [3–13] | 6.9 ± 0.7 | |
| SRC (%) | 239 ± 44 [139–339] | 145 ± 26 | 275 ± 249 | 309 ± 48 [191–426] | 350 ± 40 | 208 ± 20 |
| ROS/Proton leak (%) | 47 ± 5 [36–58] | 37 ± 7 [20–54] | 30 ± 3 | |||
| mtDNA copy number | 1692 ± 242± [1089–2293] | ND | ND | ND | ||
| mtDNA deletions | 1.00 ± 0.05± [0.87–1.13] | 0.89 ± 0.04 | 0.85 ± 0.14 | ND | ND | ND |
∗Expressed as [nmol × (min × 106 cells)−1]. RCRu, Respiratory Control Ratio under uncoupling conditions; SRC, Spare Respiratory Capacity. SRC expressed as the percentage of FCCP-induced oxygen uptake rate over the baseline one. ROS/proton leak as the percentage of oligomycin-induced oxygen uptake rate over the baseline one. ¶ Controls values for OXPHOS and enzymatic activities were taken from (Giulivi et al., 2010) and are consistent with the historic pediatric values obtained in our laboratory. ±Control values of mtDNA copy number and deletions were obtained from control male children (n = 6) with an average age of 9.6 ± 0.7 year. Data are reported as mean ± SEM for controls whereas twins’ data are expressed as mean ± SD for premutation carriers (average values obtained at three different dates, i.e., 08/15/2013, 01/27/2014 and 03/24/2016). Bolded values are below the 95% CI limit, except ROS/proton leak which is above. Bold and underlined, values ≤ 30% of control average. ND = not determined due to the limited amount of biological material available.
Mitochondrial outcomes in cultured fibroblasts from premutation twins and their mother.
| Outcome | Children controls ( | Twin 1 | Twin 2 | Adult controls ( | Mother |
|---|---|---|---|---|---|
| Substrate | |||||
| Malate-glutamate∗ | 4.6 ± 0.3 [3.8–5.4] | 3.9 ± 0.8 [1.7–6.1] | 2.2 ± 0.1 | ||
| Succinate∗ | 4.2 ± 0.9 [1.9–6.5] | 3.61 ± 0.06 | 3.8 ± 0.5 | 3.0 ± 0.4 [1.9–4.1] | |
| Complex IV activity∗ | 3.2 ± 0.4 [2.1–4.2] | 3.1 ± 0.4 [2.0–4.2] | 2.6 ± 0.2 | ||
| Citrate synthase activity∗ | 5 ± 1 [2.4–7.6] | 4.7 ± 0.3 | 5.2 ± 0.3 | 5.0 ± 0.9 [2.5–7.5] | |
| CCO/CS | 0.6 ± 0.1 [0.34–0.86] | 0.36 ± 0.09 | 0.38 ± 0.07 | 0.67 ± 0.08 [0.45–0.89] | 1.4 ± 0.7 |
| RCRu | 5.03 ± 0.50 [3.75–6.32] | 4.7 ± 0.4 [3.6–5.8] | 3.71 ± 0.03 | ||
| SRC (%) | 125 ± 8 [104–146] | 124 ± 41 | 160 ± 30 | 127 ± 2 [121–133] | 138 ± 10 |
| ROS/Proton leak (%) | 31 ± 3 [23–39] | 28 ± 3 [20–36] | |||
| mtDNA copy number | 1085 ± 120 [776–1394] | 849 ± 10 | 996 ± 80 | 918 ± 95 [654–1182] | |
| mtDNA deletions | 1.00 ± 0.04 [0.93–1.07] | 1.1 ± 0.1 | 1.0 ± 0.2 [0.8–1.2] | 1.1 ± 0.1 | |
Experimental details were described under Methods. ∗Activities expressed as [nmol oxygen consumed × (min × 106 cells)−1]. Data are shown as mean ± SEM for controls and as mean ± SD for premutation carriers. Between brackets, 95% CI built with control values obtained with fibroblasts from either male children with an average age of 8.8 ± 0.8 year (mean ± SEM) or adult females with an average age of 39.8 ± 2.5 year (mean ± SEM). Bolded values are below the 95% CI limit, except ROS/proton leak and mtDNA copy number which are above.